WASHINGTON | New COVID-19 cases are down 61% in the United States compared to the January 8 peak, health officials said on Friday, with the Department of Defense announcing military deployment in support of the vaccination campaign .
• Read also: [EN DIRECT 5 FÉVRIER] All the developments of the pandemic
According to the latest official data from February 3, new infections are down by around 121,000 cases, while hospitalizations are down by nearly 42% and the rate of deaths also seems to be slowing, detailed Rochelle Walensky, director the Centers for Disease Prevention and Control (CDC), the United States’ leading federal public health agency.
“Even though the data seems to be heading in the right direction, context is important as cases, hospitalizations, and deaths remain high and well above levels seen during the summer and early fall,” however tempered Mme Walensky during a press briefing at the White House.
The Defense Ministry announced, for its part, that it had authorized the deployment of 1,100 hired to help the five federal centers for vaccination against COVID-19. The figure could reach 10,000 soldiers.
President Biden has pledged to deliver 150 million doses within the first 100 days of his term in office, a challenge made all the more urgent by the emergence of new, more contagious variants of the coronavirus that reduce the effectiveness of drugs. vaccines.
In order to achieve this goal, Tim Manning, head of the national supply chain of the COVID-19 response team, said the government would appeal for emergency legislation called the production law of defense. The goal is to give priority to the Pfizer company to obtain the ingredients necessary for the mixture of the doses of its vaccine.
The legislative tool is also being used to support the delivery of 60 million tests to health centers or homes by the summer, and to increase the manufacturing in the United States of surgical gloves.
The U.S. Medicines Agency (FDA) is currently reviewing data submitted by Johnson & Johnson on its vaccine, ahead of an independent advisory panel meeting on February 26.
The panel is expected to issue an opinion in favor of an emergency marketing authorization, given the positive data announced by “J&J”. Clinical trials conducted on several continents have indeed shown that this vaccine, in one dose, was 66% effective, but highly protective against severe forms of COVID-19.
An emergency authorization would allow a third vaccine to be marketed in the United States, ahead of the possible authorizations given to the AstraZeneca and Novavax vaccines.